EDITORIAL article

Front. Immunol., 11 November 2024

Sec. Alloimmunity and Transplantation

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1516554

Editorial: Methods in alloimmunity and transplantation: 2023

  • 1. BIH Center for Regenerative Therapies (BCRT)

  • 2. Berlin-Brandenburg School for Regenerative Therapies (BSRT)

  • 3. Julius Wolff Institute (JWI) for Musculoskeletal Research

  • 4. Department of Nephrology and Internal Intensive Care Medicine, all three part of Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany

  • 5. Experimental Stem Cell Transplantation Group, Departments of Internal Medicine II and Department of Pediatrics, University Hospital Würzburg, Center of Experimental Molecular Medicine, Würzburg, Germany

Introduction

This Research Topic is part of the “Methods in Immunology” series, which highlights cutting-edge techniques and methods used to investigate fundamental questions in immunology research, with a focus on Alloimmunity and Transplantation (Figure 1) (1, 2). Alloimmunity is the immune response to alloantigens – immunogenic molecules from members of the same species, including blood group antigens and the highly polymorphic antigens of the major histocompatibility complex/human leukocyte antigens (MHC/HLA) (Figure 1A) (3–5). Alloantigens can be classified as major and minor mismatch antigens, which is distinguished from xenoantigens/xenoreactivity against different species, and autoantigens/autoimmunity against self-antigens (1, 3–8). Alloantigens can trigger the formation of alloantibodies through alloantigen-primed B-cells and mature plasma cells (e.g. panel-reactive vs. donor-specific antibodies, PRA vs. DSA, respectively), as part of the humoral immune response, and the activation of effector T-lymphocytes, as part of the cellular immune response, with further amplification through secondary immune cell activation and infiltration (1, 3–8). Both, humoral and cellular alloimmune responses can lead to acute and chronic graft rejection in solid organ transplantation (SOT), and graft failure or graft-versus-host disease (GVHD) in hematopoietic (stem) cell transplantation (HCT/HSCT) (9–12). The most common SOT modalities include transplantation of kidneys (KTx), liver (LiTx), lungs (LuTx), heart (HTx), and vascularized composite allografts (VCA, e.g. hand, and face Tx) (1, 2, 13, 14). Successful allo-Tx requires precise “tissue matching” and optimal “IS protocols”, to reduce the risk of immune rejection and to minimize IS toxicity (15). Current advancements in alloimmunity and transplantation (Figure 1B) include next generation sequencing (NGS) for transcriptome analysis at both bulk or single cell levels (RNAseq and scRNAseq) (16, 17), T- and B-cell receptor repertoire sequencing (TCRseq and BCRseq) (18–20), NGS analysis of donor-derived cell-free DNA (dd-cfDNA) (21–24), sophisticated in vitro and vivo models to study transplant rejection (12, 25), but also novel concepts of transplantation (Tx), immunosuppression (IS), and patient care (15), including advanced therapy medicinal products and cell and gene therapies (ATMPs and CGTs) (1, 11, 15, 26–31). Adjunct technologies include machine perfusion of donor organs, novel renal replacement therapies (RRTs), but also the exponentially increasing use of advanced bioinformatics, systems biology, and artificial intelligence, for optimal analysis and interpretation of increasingly complex/large data sets (1, 31–37).

Figure 1

Clinical application of immune repertoire sequencing in SOT

Wong et al. from the University of British Columbia and Mc Gill University in Canada, reviewed the clinical use of TCRseq and BCRseq to monitor dynamic changes in donor-reactive clonal cell populations following Tx (20), which may enable therapy adjustments to prevent rejection, reduce excessive IS, and indicate the development of tolerance. The authors reviewed 37 articles - 16 on KTx (43%) and 21 on other types (57%) and they concluded that immune repertoire sequencing is a valuable emerging tool for pre- and post-Tx monitoring.

cfDNA quantification and qualification at the first month post lung transplant

Pedini et al. from Marseille in France conducted a prospective single-center study on 62 LuTx recipients to assess the relevance of dd-cfDNA for detecting acute and chronic rejection, or infection one month post LuTx (21–23). Total cfDNA was quantified with fluorimetry and digital PCR, cfDNA fragment size with BIABooster (Adelis), and dd-cfDNA with NGS (AlloSeq). While total cfDNA levels did not correlate with patient outcomes, higher dd-cfDNA were linked to graft injuries at d30 after LuTx (P=0.0004). A threshold of 1,72% dd-cfDNA effectively identified patients with healthy grafts, while higher levels of small dd-cfDNA indicated chronic injection or infection with 100% specificity.

Podocytes as glomerular sentinels at the crossroads of innate and adaptive immunity

Burke et al. from the Miami Transplant Institute in Florida reviewed the role of podocytes in in focal segmental glomerulosclerosis (FSGS), a common glomerular disorder that manifests as nephrotic syndrome after KTx. They focused on podocytes as targets of circulating factors which promote recurrence of proteinuria following KTx. They discussed the potential of pre-/post-reperfusion biopsies and podocyte in vitro assays to develop new treatments for FSGS.

Impact of deceased-donor characteristics on early graft function in KTx donor pairs

Mahler et al. from several Eurotransplant centers in Germany analyzed the outcomes from 328 cadaveric KTx recipients using 164 paired donor kidneys. They aimed to distinguish donor related risks from recipient and procedural variables, e.g. (a)symmetry of partner graft function, defined as early graft loss or impaired graft function (eGFR <30 ml/min) 3 months post KTx. They found that while donor factors impact early graft outcomes, they may play a limited role in long-term graft survival once the kidney graft has been accepted.

Predicting BKV infection post KTx

Bae et al. from the Catholic University of Korea investigated whether pre-KTx polyomavirus (BKV) serostatus and BK-specific cell mediated immunity (IFNg-ELISPOT against five BK viral antigens, LT, St, VP1, VP2, and VP3) could predict post-KTx BKV infection by evaluating 93 donor-recipient pairs who underwent KTx vs. 44 healthy controls. A combination of elevated donor BKV-IgG, low recipient BKV-IgG, and low BKV ELISPOT accurately predicted BKV infections in KTx recipients, helping clinicians to intervene earlier.

Autoantibodies from patients with KTx allograft vasculopathy promote inflammation

Moll et al. from Charité Berlin discovered that non-HLA-directed, protease activated receptor 1 (PAR1)-/G-protein coupled receptor (GPCR)-targeting regulatory autoantibodies (RABs) from KTx patients with transplant vasculopathy, but not IgG from KTx patients without vasculopathy or healthy controls, can exert immune stimulatory effects, triggering intracellular, and extracellular signaling in human microvascular endothelial cells and monocytic cells that may contribute to vasculopathy and graft failure, irrespective of alloantigen-directed responses.

Expanded hemodialysis ameliorates uremia-induced endothelial dysfunction

Zhao et al. from Charité Berlin found that expanded hemodialysis (HDx) with medium-cutoff (MCO) membranes can reduce endothelial dysfunction caused by uremia in HD patients. In turn, HDx therapy preserved the vasculoprotective Krüppel-like factor 2 (KLF2), which counteracts inflammation and promotes vascular health.

Better outcomes for HSCT recipients treated in home care versus hospital isolation

Ringdén et al. from Karolinska Institutet in Stockholm, Sweden, reviewed their >20-year “Karolinska Experience” providing home care to HSCT patients starting in 1998. Analyzing 252 allo-HSCT patient outcomes they found that home care is safe, reduces the risk of developing acute GVHD, lowers transplant-related mortality, improves survival, and decreases proinflammatory cytokine levels compared to hospital-treated controls.

Autoimmune encephalitis, neurological symptoms, and neuronal antibody in HSCT

Zhang et al. from Tongji Medical College in Wuhan, China, reported a case of neuronal surface antibody syndrome (NSAS)-related autoimmune neurological disorder, with presentation of autoimmune encephalitis (AE), in a 7-year-old girl following HSCT, diagnosed with anti-metabotropic glutamate receptor-5 (mGluR5) autoimmunity, a less common form of NSAS-related autoimmunity. Treatment with IVIG and methylprednisolone, followed by oral prednisone tablets, and levetiracetam as antiepileptic therapy led to significant improvement.

Ex vivo modeling of intestinal GVHD with a novel T-cell-organoid coculture system

Matthe et al. from the University Hospital Erlangen and University of Erlangen-Nuremberg in Germany developed a novel T-cell-organoid (co)culture system to study lympho-epithelial interactions in intestinal GvHD, which provides a valuable ex vivo platform for screening new therapeutic strategies on cellular and molecular level.

Novel preclinical mouse model for cGVDH

Verlaat et al. from Charité Berlin report the development of two murine cGvHD models, which display high long-term morbidity, but low mortality, and depict heterogeneous clinical manifestations seen of cGVDH pathophysiology seen in patients.

Statements

Author contributions

GM: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. AB: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AB was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 324392634 – TRR 221. GM was supported by grants from the German Federal Ministry of Education and Research (BMBF) and the DFG (EXPAND-PD project #CA2816/1) and through the BIH Center for Regenerative Therapies (BCRT) and the Berlin-Brandenburg School for Regenerative Therapies (BSRT: GSC203), respectively, and in part by the European Union’s Horizon 2020 Research and Innovation Program und the grant agreements No 733006 (PACE), 779293 (HIPGEN), 754995 (EU-TRAIN), and 101095635 (PROTO). We acknowledge financial support from the Open Access Publication Fund of Charité Universitätsmedizin Berlin and the DFG.

Acknowledgments

We would like to thank all authors who contributed submitting manuscripts to this Research Topic and all reviewers who provided insightful feedback and helpful comments. All listed authors have made a substantial direct intellectual contribution, approved it for publication, and declare that the research was conducted in the absence of any potential conflict of interest.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    MollGLimWHPenackO. Editorial: Emerging talents in alloimmunity and transplantation: 2022. Front Immunol. (2024) 15:1393026. doi: 10.3389/fimmu.2024.1393026

  • 2

    MollGDaiZCamaraNOS. Editorial: advances in heart transplantation. Front Immunol. (2022) 13:960800. doi: 10.3389/fimmu.2022.960800

  • 3

    RochaPNPlumbTJCrowleySDCoffmanTM. Effector mechanisms in transplant rejection. Immunol Rev. (2003) 196:51–64. doi: 10.1046/j.1600-065X.2003.00090.x

  • 4

    FelixNJAllenPM. Specificity of T-cell alloreactivity. Nat Rev Immunol. (2007) 7:942–53. doi: 10.1038/nri2200

  • 5

    ElyLKBurrowsSRPurcellAWRossjohnJMcCluskeyJ. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr Opin Immunol. (2008) 20:575–80. doi: 10.1016/j.coi.2008.07.006

  • 6

    GaliliU. Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfus Apher Sci. (2006) 35:45–58. doi: 10.1016/j.transci.2006.05.007

  • 7

    Cabral-MarquesOMollGCatarRPreußBBankampLPecherA-Cet al. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. Autoimmun Rev. (2023) 22:103310. doi: 10.1016/j.autrev.2023.103310

  • 8

    MollGHultAvon BahrLAlmJJHeldringNHamadOAet al. Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS One. (2014) 9:e85040. doi: 10.1371/journal.pone.0085040

  • 9

    CordesSMokhtariZBartosovaMMertlitzSRiesnerKShiYet al. Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica. (2021) 106:2147–60. doi: 10.3324/haematol.2020.253716

  • 10

    UllrichEBeilhackAWolfD. Editorial: novel and improved methods for the prevention and treatment of graft-versus-host disease (GVHD). Front Immunol. (2022) 13:966389. doi: 10.3389/fimmu.2022.966389

  • 11

    RingdénOMollGGustafssonBSadeghiB. Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of graft-versus-host disease, Hemorrhages and Acute Respiratory Distress Syndrome. Front Immunol. (2022) 13:839844. doi: 10.3389/fimmu.2022.839844

  • 12

    PenackOMarchettiMAljurfMAratMBonifaziFDuarteRFet al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, The Lancet. Haematology. (2024) 11:e147–59. doi: 10.1016/S2352-3026(23)00342-3

  • 13

    KnoedlerLDeanJDiattaFThompsonNKnoedlerSRhysRet al. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1372862

  • 14

    Kauke-NavarroMNoelOFKnoedlerLKnoedlerSPanayiACStoegnerVAet al. Novel strategies in transplantation: genetic engineering and vascularized composite allotransplantation. J Surg Res. (2023) 291:176–86. doi: 10.1016/j.jss.2023.04.028

  • 15

    RoemhildAOttoNMMollGAbou-El-EneinMKaiserDBoldGet al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. Bmj. (2020) 371:m3734. doi: 10.1136/bmj.m3734

  • 16

    AndrzejewskaACatarRSchoonJQaziTHSassFAJacobiDet al. Multi-parameter analysis of biobanked human bone marrow stromal cells shows little influence for donor age and mild comorbidities on phenotypic and functional properties. Front Immunol. (2019) 10:2474. doi: 10.3389/fimmu.2019.02474

  • 17

    VandereykenKSifrimAThienpontBVoetT. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. (2023) 24:494–515. doi: 10.1038/s41576-023-00580-2

  • 18

    FreemanJDWarrenRLWebbJRNelsonBHHoltRA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res. (2009) 19:1817–24. doi: 10.1101/gr.092924.109

  • 19

    DziubianauMHechtJKuchenbeckerLSattlerAStervboURodelspergerCet al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant. (2013) 13:2842–54. doi: 10.1111/ajt.12431

  • 20

    AlachkarHMutongaMKatoTKalluriSKakutaYUemuraMet al. Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection. BMC Nephrol. (2016) 17:181. doi: 10.1186/s12882-016-0395-3

  • 21

    TamkovichSNVlassovVVLaktionovPP. Circulating DNA in the blood and its application in medical diagnosis. Mol Biol. (2008) 42:9–19. doi: 10.1134/S0026893308010020

  • 22

    JiangPLoYMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. (2016) 32:360–71. doi: 10.1016/j.tig.2016.03.009

  • 23

    KnightSRThorneALo FaroML. Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A systematic review. Transplantation. (2019) 103:273–83. doi: 10.1097/TP.0000000000002482

  • 24

    OellerichMSherwoodKKeownPSchützEBeckJStegbauerJet al. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol. (2021) 17:591–603. doi: 10.1038/s41581-021-00428-0

  • 25

    JiangXShiQSWuC-YXuLYangHMedhatAskar. Investigative and laboratory assays for allogeneic rejection – A clinical perspective. Transplant Rep. (2023) 8:100133. doi: 10.1016/j.tpr.2023.100133

  • 26

    MollGHoogduijnMJAnkrumJA. Editorial: safety, efficacy and mechanisms of action of mesenchymal stem cell therapies. Front Immunol. (2020) 11:243. doi: 10.3389/fimmu.2020.00243

  • 27

    MollGAnkrumJAKamhieh-MilzJBiebackKRingdenOVolkHDet al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. (2019) 25:149–63. doi: 10.1016/j.molmed.2018.12.006

  • 28

    MollGAnkrumJAOlsonSDNoltaJA. Improved MSC minimal criteria to maximize patient safety: A call to embrace tissue factor and hemocompatibility assessment of MSC products. Stem Cells Trans Med. (2022) 11:2–13. doi: 10.1093/stcltm/szab005

  • 29

    GoldsobelGvon HerrathCSchlickeiserSBrindleNStählerFReinkePet al. RESTORE survey on the public perception of advanced therapies and ATMPs in europe-why the european union should invest more! Front Med (Lausanne). (2021) 8:739987. doi: 10.3389/fmed.2021.739987

  • 30

    BerishviliEPiemontiLde KoningEJPLindstedtSScholzHScottWEet al. ESOT roadmap for advanced therapy medicinal products in transplantation: navigating regulatory challenges to enhance access and care. Transplant Int. (2024) 37. doi: 10.3389/ti.2024.13485

  • 31

    Silva-SousaTUsudaJNAl-AraweNFriasFHinterseherICatarRet al. The global evolution and impact of systems biology and artificial intelligence in stem cell research and therapeutics development: A scoping review. Stem Cells. (2024). doi: 10.1093/stmcls/sxae054

  • 32

    TatumRO’MalleyTJBodzinASTchantchaleishviliV. Machine perfusion of donor organs for transplantation. Artif organs. (2021) 45:682–95. doi: 10.1111/aor.13894

  • 33

    BasileCDavenportAMitraSPalAStamatialisDChrysochouCet al. Frontiers in hemodialysis: Innovations and technological advances. Artif organs. (2021) 45:175–82. doi: 10.1111/aor.13798

  • 34

    CatarRMollGKamhieh-MilzJLuechtCChenLZhaoHet al. Expanded hemodialysis therapy ameliorates uremia-induced systemic microinflammation and endothelial dysfunction by modulating VEGF, TNF-α and AP-1 signaling. Front Immunol. (2021) 12:774052. doi: 10.3389/fimmu.2021.774052

  • 35

    LoupyAMengelMHaasM. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. Kidney Int. (2022) 101:678–91. doi: 10.1016/j.kint.2021.11.028

  • 36

    YooDGoutaudierVDivardGGueguenJAstorBCAubertOet al. An automated histological classification system for precision diagnostics of kidney allografts. Nat Med. (2023) 29:1211–20. doi: 10.1038/s41591-023-02323-6

  • 37

    YooDDivardGRaynaudMCohenAMoneTDRosenthalJTet al. A machine learning-driven virtual biopsy system for kidney transplant patients. Nat Commun. (2024) 15:554. doi: 10.1038/s41467-023-44595-z

Summary

Keywords

transplantation, alloimmunity, rejection, inflammation, cell therapy, immunosuppression, immunomodulation, methods/technology

Citation

Moll G and Beilhack A (2024) Editorial: Methods in alloimmunity and transplantation: 2023. Front. Immunol. 15:1516554. doi: 10.3389/fimmu.2024.1516554

Received

24 October 2024

Accepted

28 October 2024

Published

11 November 2024

Volume

15 - 2024

Edited and reviewed by

Antoine Toubert, Université Paris Cité, France

Updates

Copyright

*Correspondence: Guido Moll, ; Andreas Beilhack,

†ORCID: Guido Moll, orcid.org/0000-0001-6173-5957; Andreas Beilhack, orcid.org/0000-0002-3165-2648

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics